Cédrik Lafond

702 total citations
12 papers, 260 citations indexed

About

Cédrik Lafond is a scholar working on Otorhinolaryngology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Cédrik Lafond has authored 12 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Otorhinolaryngology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in Cédrik Lafond's work include Head and Neck Cancer Studies (10 papers), Lung Cancer Treatments and Mutations (6 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Cédrik Lafond is often cited by papers focused on Head and Neck Cancer Studies (10 papers), Lung Cancer Treatments and Mutations (6 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Cédrik Lafond collaborates with scholars based in France, Switzerland and Spain. Cédrik Lafond's co-authors include Laurent Martin, Jean Bourhis, Christian Sire, Alexandre Coutté, Yungan Tao, J. Guigay, Lionnel Geoffrois, Frédéric Rolland, Caroline Even and X. Liem and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Supportive Care in Cancer.

In The Last Decade

Cédrik Lafond

12 papers receiving 258 citations

Peers

Cédrik Lafond

ONCOL

OTORH

PRM

SURGE

IMMUN

Franck Drouet France

Igor Lifirenko Russia

Dtt Chua China

Wei-Xiong Xia China

Yan-Fang Ye China

N Moeckelmann Germany

Joaquín Belón Spain

Shu‐Hui Lv China

Ann Tan United States

Chuanben Chen China

Franck Drouet France

Cédrik Lafond

103 ×0.6

ONCOL

52 ×0.3

OTORH

70 ×0.6

PRM

41 ×0.5

SURGE

25 ×0.7

IMMUN

Citations per year, relative to Cédrik Lafond Cédrik Lafond (= 1×) peers Franck Drouet

Countries citing papers authored by Cédrik Lafond

Since Specialization

Citations

This map shows the geographic impact of Cédrik Lafond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cédrik Lafond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cédrik Lafond more than expected).

Fields of papers citing papers by Cédrik Lafond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cédrik Lafond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cédrik Lafond. The network helps show where Cédrik Lafond may publish in the future.

Co-authorship network of co-authors of Cédrik Lafond

This figure shows the co-authorship network connecting the top 25 collaborators of Cédrik Lafond. A scholar is included among the top collaborators of Cédrik Lafond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cédrik Lafond. Cédrik Lafond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Tao, Yungan, Anne Aupérin, Xu-Shan Sun, et al.. (2020). Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). European Journal of Cancer. 141. 21–29. 58 indexed citations

Guigay, J., Jérôme Fayette, Ricard Mesı́a, et al.. (2020). TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology. 38(15_suppl). 6507–6507. 14 indexed citations

Licitra, Lisa, Robert I. Haddad, Caroline Even, et al.. (2019). EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology. 37(15_suppl). 6012–6012. 31 indexed citations

Guigay, J., Jérôme Fayette, Ricard Mesı́a, et al.. (2019). TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology. 37(15_suppl). 6002–6002. 46 indexed citations

Tao, Yungan, Anne Aupérin, Xu Sun, et al.. (2018). Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH).. Journal of Clinical Oncology. 36(15_suppl). 6076–6076. 17 indexed citations

Tao, Yungan, M. Alfonsi, Pierre Boisselier, et al.. (2018). Hyperfractionated reirradiation with cetuximab for recurrent head and neck cancer: The GORTEC 2008-01 multicentric phase II study.. Journal of Clinical Oncology. 36(15_suppl). 6034–6034. 2 indexed citations

Sun, Xu, Christian Sire, Yungan Tao, et al.. (2018). A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.. Journal of Clinical Oncology. 36(15_suppl). 6018–6018. 42 indexed citations

Lizée, T., Anne-Lise Septans, Y. Pointreau, et al.. (2017). Digestive toxicities after palliative three-dimensional conformal radiation therapy (3D-CRT) for cervico-thoracic spinal metastases. Supportive Care in Cancer. 26(6). 1897–1903. 2 indexed citations

Bourhis, Jean, Anne Aupérin, M. Alfonsi, et al.. (2017). Dose escalation of radiotherapy (RT) for locally advanced head and neck carcinomas treated with concomitant chemotherapy (CT) and RT: Results of the GORTEC 2004-01 randomized trial.. Journal of Clinical Oncology. 35(15_suppl). 6015–6015. 6 indexed citations

10.

Tao, Yungan, Lionnel Geoffrois, Laurent Martin, et al.. (2017). Impact of p16 expression on induction taxotere-cisplatin-5 FU (TPF) followed by cetuximab-radiotherapy in N2b-N3 head and neck squamous cell carcinoma (HNSCC): Results of GORTEC 2007-02 phase III randomized trial.. Journal of Clinical Oncology. 35(15_suppl). 6070–6070. 6 indexed citations

11.

Geoffrois, Lionnel, Laurent Martin, P. Garaud, et al.. (2016). Induction docetaxel platinum 5-FU (TPF) followed by cetuximab-radiotherapy (cetux-RT) versus concurrent chemo-radiotherapy (CT/RT) in patients with N2b/c-N3 non operated stage III-IV squamous cell cancer of the head and neck (SCCHN): Results of the GORTEC 2007-02 phase III randomized trial.. Journal of Clinical Oncology. 34(15_suppl). 6000–6000. 26 indexed citations

12.

Guigay, J., H. Le Caer, C. Mertens, et al.. (2014). Elderly Head and Neck Cancer (ELAN) study: Personalized treatment according to geriatric assessment in patients age 70 or older: First prospective trials in patients with squamous cell cancer of the head and neck (SCCHN) unsuitable for surgery.. Journal of Clinical Oncology. 32(15_suppl). TPS6099–TPS6099. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact